Caspase 3 inactivation protects against hepatic cell death and ameliorates fibrogenesis in a diet-induced NASH model

Digestive Diseases and Sciences

Volumn 59, Issue 6, 2014, Pages 1197-1206

  Thapaliya, Samjhana ^a   Wree, Alexander ^b   Povero, Davide ^b   Inzaugarat, Maria Eugenia ^b   Berk, Michael ^a   Dixon, Laura ^a   Papouchado, Bettina G ^c   Feldstein, Ariel E ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Caspases; Liver fibrosis; Liver injury; Nonalcoholic fatty liver disease

Indexed keywords

AMINOTRANSFERASE; CASPASE 3; CHEMOKINE RECEPTOR CCR2; COLLAGEN; CYTOKINE; LYMPHOCYTE ANTIGEN; LYMPHOCYTE ANTIGEN 6 COMPLEX LOCUS C1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME INACTIVATION; FIBROGENESIS; INFLAMMATION; INFLAMMATORY INFILTRATE; LIVER FIBROSIS; LIVER INJURY; LIVER PROTECTION; MONOCYTE; MOUSE; NAFLD ACTIVITY SCORE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, LY; APOPTOSIS; CASPASE 3; CHOLINE; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY LIVER; GENE EXPRESSION REGULATION; HEPATIC STELLATE CELLS; HEPATOCYTES; LIVER CIRRHOSIS; METHIONINE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, CCR2;

EID: 84902256769     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3167-6     Document Type: Article

References (40)

1. Wieckowska A, Feldstein AE. Nonalcoholic fatty liver disease in the pediatric population: a review. Curr Opin Pediatr. 2005;17:636-641. (Pubitemid 41406127)
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231.
3. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-1395. (Pubitemid 39657013)
4. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118:1388-1393. (Pubitemid 46393782)
5. Wieckowska A, Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis. 2008;28:386-395.
6. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology . 2005;129:113-121. (Pubitemid 41002048)
7. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413-1419. (Pubitemid 29258890)
8. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term followup of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865-873. (Pubitemid 46489550)
9. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 2003;125:437-443. (Pubitemid 36929425)
10. Cazanave SC, Gores GJ. Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin Lipidol. 2010;5:71-85.
11. Li J, Yuan J. Caspases in apoptosis and beyond. Oncogene. 2008;27:6194-6206.
12. Weber IT, Fang B, Agniswamy J. Caspases: structure-guided design of drugs to control cell death. Mini Rev Med. 2008;8:1154-1162.
13. Pop C, Salvesen GS. Human caspases: activation, specificity, and regulation. J Biol Chem. 2009;284:21777-21781.
14. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem. 1999;68:383-424. (Pubitemid 29449198)
15. Fuentes-Prior P, Salvesen GS. The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem J. 2004;384:201-232. (Pubitemid 39656233)
16. Feldstein A, Gores GJ. Steatohepatitis and apoptosis: therapeutic implications. Am J Gastroenterol. 2004;99:1718-1719. (Pubitemid 39237498)
17. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006;44:27-33. (Pubitemid 44049136)
18. Hatting M, Zhao G, Schumacher F, et al. Hepatocyte caspase-8 is an essential modulator of steatohepatitis in rodents. Hepatology. 2013;57:2189-2201.
19. Dixon LJ, Flask CA, Papouchado BG, Feldstein AE, Nagy LE. Caspase-1 as a central regulator of high fat diet-induced nonalcoholic steatohepatitis. PLoS One. 2013;8:e56100.
20. Woo M, Hakem R, Soengas MS, et al. Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev. 1998;12:806-819. (Pubitemid 28150882)
21. Nanji AA. Animal models of nonalcoholic fatty liver disease and steatohepatitis. Clinics in Liver Disease. 2004;8:559-574, ix. (Pubitemid 39141143)
22. Koteish A, Diehl AM. Animal models of steatosis. Semin Liver Dis. 2001;21:89-104. (Pubitemid 32240489)
23. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321. (Pubitemid 40770284)
24. Alkhouri N, Dixon LJ, Feldstein AE. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev Gastroenterol Hepatol. 2009;3:445-451.
25. Feldstein AE, Gores GJ. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci. 2005;10:3093-3099. (Pubitemid 40910547)
26. Li Z, Berk M, McIntyre TM, Gores GJ, Feldstein AE. The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology. 2008;47:1495-1503. (Pubitemid 351702733)
27. Feldstein AE, Canbay A, Guicciardi ME, Higuchi H, Bronk SF, Gores GJ. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol. 2003;39:978-983. (Pubitemid 37523769)
28. Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology. 2004;40:185-194. (Pubitemid 38868937)
29. Green DR. Apoptotic pathways: ten minutes to dead. Cell. 2005;121:671-674. (Pubitemid 40797590)
30. Chowdhury I, Tharakan B, Bhat GK. Caspases - an update. Comp Biochem Physiol B Biochem Mol Biol. 2008;151:10-27.
31. Barreyro FJ, Holod S, Finocchietto PV et al. The pan-caspase inhibitor emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2014. (Epub ahead of print). doi:10.1111/liv.12570.
32. Witek RP, Stone WC, Karaca FG, et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology. 2009;50:1421-1430.
33. Anstee QM, Concas D, Kudo H, et al. Impact of pan-caspase inhibition in animal models of established steatosis and nonalcoholic steatohepatitis. J Hepatol. 2010;53:542-550.
34. Alkhouri N, Gornicka A, Berk MP, et al. Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis. J Biol Chem. 2010;285:3428-3438.
35. Syn WK, Choi SS, Diehl AM. Apoptosis and cytokines in nonalcoholic steatohepatitis. Clin Liver Dis. 2009;13:565-580.
36. Imamura M, Ogawa T, Sasaguri Y, Chayama K, Ueno H. Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology. 2005;128:138-146. (Pubitemid 40039965)
37. Seki E, De Minicis S, Gwak GY, et al. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Investig. 2009;119:1858-1870.
38. Tacke F. Functional role of intrahepatic monocyte subsets for the progression of liver inflammation and liver fibrosis in vivo. Fibrogenesis Tissue Repair. 2012;5:S27.
39. Karlmark KR, Weiskirchen R, Zimmermann HW, et al. Hepatic recruitment of the inflammatory Gr1 + monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology. 2009;50:261-274.
40. Seki E, de Minicis S, Inokuchi S, et al. CCR2 promotes hepatic fibrosis in mice. Hepatology. 2009;50:185-197.